This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), CureVac (CVAC) and AnaptysBio (ANAB)

Tipranks - Tipranks - Wed Jun 18, 2025

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Immuneering (IMRX – Research Report), CureVac (CVAC – Research Report) and AnaptysBio (ANAB – Research Report).

Confident Investing Starts Here:

Immuneering (IMRX)

Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Immuneering yesterday and set a price target of $8.00. The company’s shares closed last Monday at $2.37.

According to TipRanks.com, Suvannavejh is ranked 0 out of 5 stars with an average return of -7.6% and a 40.0% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Amylyx Pharmaceuticals Inc, and Neumora Therapeutics, Inc. ;'>

Currently, the analyst consensus on Immuneering is a Moderate Buy with an average price target of $15.00, representing a 614.3% upside. In a report issued on June 5, Needham also maintained a Buy rating on the stock with a $9.00 price target.

See the top stocks recommended by analysts >>

CureVac (CVAC)

In a report issued on June 12, Mani Foroohar from Leerink Partners maintained a Hold rating on CureVac. The company’s shares closed last Monday at $5.52.

According to TipRanks.com, Foroohar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -11.0% and a 40.6% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as CAMP4 Therapeutics Corporation, Recursion Pharmaceuticals, and 4D Molecular Therapeutics. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for CureVac with a $5.50 average price target, a -0.5% downside from current levels. In a report issued on June 12, Citizens JMP also downgraded the stock to Hold.

AnaptysBio (ANAB)

Leerink Partners analyst David Risinger maintained a Buy rating on AnaptysBio on June 12. The company’s shares closed last Monday at $23.90.

According to TipRanks.com, Risinger is a 5-star analyst with an average return of 8.7% and a 54.1% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Centessa Pharmaceuticals, and Vertex Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for AnaptysBio with a $50.86 average price target, an 117.4% upside from current levels. In a report issued on June 4, H.C. Wainwright also upgraded the stock to Buy with a $38.00 price target.

Read More on IMRX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).